A prospective clinical utility study demonstrates that physicians use the 40-gene expression profile (40-GEP) to guide clinical management decisions for Medicare-eligible patients with cutaneous squamous cell carcinoma (cSCC). J of Skin. 2022;6(6):s95. doi:10.25251/skin.6.supp.95